The Atriva Approach

Already in 2001 our scientific founders published a new antiviral mode of action. The Journal “Nature Cell Biology” stated on their title page: “Inhibiting Raf and fighting flu”. This simple but very meaningful headline is now referred to The ATRIVA Approach.

External Link

The Atriva Approach

The Atriva Approach

ATRIVA is changing the philosophy and strategy of antiviral drug development. Instead of targeting the virus directly, the ATRIVA compound are directed against a cellular factor of the host cell. In order to ensure efficient replication, the virus needs to activate this factor. ATRIVA lead compound ATR-002 prevent the virus-induced activation of the cellular factor and consequently viral replication.

Approach Virus

Various viruses need to activate this cellular factor for replication, including viruses responsible for respiratory tract infections. Thus, ATR002 might not only be effective against influenza virus but also against others viruses that lead to influenza like illness. Consequently ATR002 will be developed as the first-in-class compound against influenza- and other respiratory viruses.



For detail and further readings:

Pleschka et al. 2001; Influenza virus propagation is impaired by inhibition of the Raf/MEK/ERK signalling cascade Nature Cell Biology 3:301–305.

Droebner et al. 2011; Antiviral activity of the MEK-inhibitor U0126 against pandemic H1N1v and highly pathogenic avian influenza virus in vitro and in vivo. Antiviral Research 92:195-203.

Planz 2013; Development of cellular signaling pathway inhibitors as new antivirals against influenza. Antiviral Research 98:457-468

PHaasbach et al 2017; The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity in vitro and provides a prolonged treatment window compared to standard of care in vivo. Antiviral Research 142:178-184.


Atriva Therapeutics GmbH
Christophstr. 32, 72072 Tübingen

+49 (0)7071 8597673